CITI/CALL/ELI LILLY & CO/520/0.1/19.12.24 | Delayed Deutsche Boerse AG 01:55:35 12/07/2024 pm IST | ||
| 39.37 EUR | +1.65% |
|
| Current month | +1.89% | ||
| 1 month | +16.66% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 12/24/12 | 39.37 | +1.65% |
| 11/24/11 | 38.73 | -2.98% |
| 10/24/10 | 39.92 | +2.78% |
| 09/24/09 | 38.84 | +2.10% |
| 08/24/08 | 38.04 | +1.01% |
Delayed Quote Deutsche Boerse AG
Last update July 12, 2024 at 01:55 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Citi
|
| WKN | KH76YF |
| ISIN | DE000KH76YF8 |
| Date issued | 19/07/2023 |
| Strike | 520 $ |
| Maturity | 19/12/2024 (161 Days) |
| Parity | 10 : 1 |
| Emission price | 3.54 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40.42 € |
|---|---|
| Lowest since issue | 3.71 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
934.1
USD
Average target price
887.2
USD
Spread / Average Target
-5.03%
- Stock Market
- Warrants
- Warrant
